Cellebrite DI (NASDAQ:CLBT) Given New $28.00 Price Target at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its price target raised by JPMorgan Chase & Co. from $24.00 to $28.00 in a research note released on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts also recently commented on the stock. Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC boosted their price target on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI has an average rating of “Buy” and an average price target of $22.14.

Cellebrite DI Trading Down 12.9 %

Shares of Cellebrite DI stock opened at $21.70 on Tuesday. The firm has a market capitalization of $4.47 billion, a PE ratio of -14.00, a price-to-earnings-growth ratio of 3.72 and a beta of 1.47. The firm’s 50 day moving average is $22.57 and its 200 day moving average is $19.09. Cellebrite DI has a 1 year low of $9.22 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. As a group, research analysts anticipate that Cellebrite DI will post 0.32 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CLBT. Quarry LP bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at $27,000. Advisors Asset Management Inc. increased its stake in shares of Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after acquiring an additional 1,742 shares in the last quarter. Pathway Financial Advisers LLC increased its stake in shares of Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after acquiring an additional 4,118 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of Cellebrite DI in the 4th quarter valued at $100,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.